Pharmacology

Anthony Letai discusses how understanding programmed cell death can guide the selection of cancer treatments. The seminar explains how apoptotic signalling can be measured and how these measurements can identify drugs capable of killing cancer cells. Hybrid: New Research Building Auditorium, Georgetown University Medical Center, Washington, DC, and Zoom. Monday 5 October 2026, 16:30–17:30 EDT (America/New_York; UTC−4). Use the attendance registration form or the event’s Zoom link on the organizer page. Organized by Georgetown’s Distinguished Scientist Seminar Series. Letai is Director of the National Cancer Institute. An in-person reception follows the seminar.

Kuan Hong Wang examines how dopaminergic, cannabinoid, and neuroimmune signaling regulate circuit plasticity across development, experience, and disease, and how cross-species work may inform selective therapies.

A Keystone Symposium connecting genetics, functional genomics, developmental neurobiology, and industry to identify convergent mechanisms and therapeutic opportunities in neurodevelopmental disorders.

This Keystone Symposium examines how nerves and neural activity shape cancer initiation, progression, metastasis, cognition, and treatment, with a focus on actionable therapeutic targets.

FAPESP-supported postdoctoral fellowship in São Paulo investigating malaria drug discovery and cellular signalling. The project studies new molecular targets, GPCR-like receptors and therapeutic strategies against Plasmodium falciparum. One position is advertised under project 2023/07656-0. Applicants should send a CV and cover or motivation letter describing relevant experience to the investigator listed on the official opportunity page by 12 October.

Mandatory expression-of-interest stage for research on medical countermeasures to improve UK preparedness for CBRN incidents. Projects may develop or test therapeutics, diagnostics, medical devices and other interventions through early clinical studies. The programme allows up to GBP4 million per application, funds 80% of full economic cost and supports projects up to 30 months. Submit the required EOI form and the funder-requested email by 20 October 2026 at 16:00 UK time. Invited full applications open on 5 November 2026.

Funds experimental advancement of AI-discovered therapeutic leads for Alzheimer’s disease and related dementias. Separate tracks support lead optimization and work enabling an investigational-new-drug submission. Awards are up to USD 1 million over two to three years. Pure algorithm development, general AI platforms, repurposing and clinical trial execution are excluded. Letters of intent are due 20 October 2026 at 17:00 Eastern time (22 October for ISTAART members); invited full applications follow on 15 December (17 December for members).

Kristina Johnell’s group at the Department of Medical Epidemiology and Biostatistics uses Swedish register data to study medication use, safety, COVID-19 and deprescribing in older adults. The researcher will develop questions and study designs, manage and analyse large datasets, interpret results, lead scientific articles and contribute to supervision, grant applications and collaborations. This full-time position in Solna is initially for two years, with possible extension. Applications through Varbi close on 26 October 2026.

Kristina Johnell’s group at the Department of Medical Epidemiology and Biostatistics uses Swedish register data to study medication use, safety, COVID-19 and deprescribing in older adults. The researcher will develop questions and study designs, manage and analyse large datasets, interpret results, lead scientific articles and contribute to supervision, grant applications and collaborations. This full-time position in Solna is initially for two years, with possible extension. Applications through Varbi close on 26 October 2026.

Develop biochemical and cellular assay strategies for drug-discovery programmes, connecting experimental pharmacology with AI-generated hypotheses. Responsibilities include target validation, screening cascades, functional assays and biophysical measurements, with emphasis on oncology and immunology. Lead external experimental work and collaborate across scientific teams. The current employer page accepts applications and states no fixed deadline.

Support in vivo pharmacology for RNA therapeutics by carrying out rodent efficacy studies, dosing and sample collection. The work connects animal experiments with molecular measurements including PCR-based assays, ELISA and western blotting, in collaboration with the discovery team. This is a full-time, on-site position. The advertised base salary range is USD 90,000–110,000. Apply through the employer’s current Lever vacancy; no fixed closing date is stated.

Kuan Hong Wang examines how dopaminergic, cannabinoid, and neuroimmune signaling regulate circuit plasticity across development, experience, and disease, and how cross-species work may inform selective therapies.